189 related articles for article (PubMed ID: 26020272)
41. Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy.
Cao S; Wang S; Ma H; Tang S; Sun C; Dai J; Wang C; Shu Y; Xu L; Yin R; Song X; Chen H; Han B; Li Q; Wu J; Bai C; Chen J; Jin G; Hu Z; Lu D; Shen H
Pharmacogenomics J; 2016 Feb; 16(1):41-6. PubMed ID: 25823687
[TBL] [Abstract][Full Text] [Related]
42. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer.
Cortes J; Rodriguez J; Aramendia JM; Salgado E; Gurpide A; Garcia-Foncillas J; Aristu JJ; Claver A; Bosch A; Lopez-Picazo JM; Martin-Algarra S; Brugarolas A; Calvo E
Oncology; 2003; 64(1):28-35. PubMed ID: 12457029
[TBL] [Abstract][Full Text] [Related]
43. Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients.
Ke HG; Li J; Shen Y; You QS; Yan Y; Dong HX; Liu JH; Shen ZY
Asian Pac J Cancer Prev; 2012; 13(9):4413-6. PubMed ID: 23167352
[TBL] [Abstract][Full Text] [Related]
44. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.
Gridelli C; Gallo C; Shepherd FA; Illiano A; Piantedosi F; Robbiati SF; Manzione L; Barbera S; Frontini L; Veltri E; Findlay B; Cigolari S; Myers R; Ianniello GP; Gebbia V; Gasparini G; Fava S; Hirsh V; Bezjak A; Seymour L; Perrone F
J Clin Oncol; 2003 Aug; 21(16):3025-34. PubMed ID: 12837810
[TBL] [Abstract][Full Text] [Related]
45. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
Qian CY; Zheng Y; Wang Y; Chen J; Liu JY; Zhou HH; Yin JY; Liu ZQ
Chin J Cancer; 2016 Sep; 35(1):85. PubMed ID: 27590272
[TBL] [Abstract][Full Text] [Related]
46. Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.
Petrioli R; Francini E; Fiaschi AI; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Bianco V; Roviello G
Med Oncol; 2015 Apr; 32(4):134. PubMed ID: 25796503
[TBL] [Abstract][Full Text] [Related]
47. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
48. Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.
Wu W; Li H; Wang H; Zhao X; Gao Z; Qiao R; Zhang W; Qian J; Wang J; Chen H; Wei Q; Han B; Lu D
PLoS One; 2012; 7(3):e33200. PubMed ID: 22479369
[TBL] [Abstract][Full Text] [Related]
49. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Feng J; Sun X; Sun N; Qin S; Li F; Cheng H; Chen B; Cao Y; Ma J; Cheng L; Lu Z; Ji J; Zhou Y
Acta Biochim Biophys Sin (Shanghai); 2009 May; 41(5):429-35. PubMed ID: 19430706
[TBL] [Abstract][Full Text] [Related]
50. Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy.
Fujita S; Masago K; Hatachi Y; Fukuhara A; Hata A; Kaji R; Kim YH; Mio T; Mishima M; Katakami N
BMC Med Genet; 2010 Nov; 11():167. PubMed ID: 21114867
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Masuda T; Imai H; Kuwako T; Miura Y; Yoshino R; Kaira K; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
Clin Transl Oncol; 2015 Sep; 17(9):702-9. PubMed ID: 25990507
[TBL] [Abstract][Full Text] [Related]
52. A phase II trial of weekly paclitaxel and gemcitabine in non-small cell lung cancer patients previously treated with platinum and vinorelbine.
Dongiovanni V; Addeo A; Berruti A; Buffoni L; Dongiovanni D; Polimeni MA; Fissore C; Barone C; Bertetto O
Anticancer Res; 2004; 24(4):2567-72. PubMed ID: 15330216
[TBL] [Abstract][Full Text] [Related]
53. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Matano E; Boni C; Marangolo M; Failla G; Altavilla G; Adamo V; Ceribelli A; Clerici M; Di Costanzo F; Frontini L; Tonato M;
J Clin Oncol; 2002 Nov; 20(21):4285-91. PubMed ID: 12409326
[TBL] [Abstract][Full Text] [Related]
54. Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer.
Lilenbaum RC; Chen CS; Chidiac T; Schwarzenberger PO; Thant M; Versola M; Lane SR
Ann Oncol; 2005 Jan; 16(1):97-101. PubMed ID: 15598945
[TBL] [Abstract][Full Text] [Related]
55. A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer.
Cheng J; Ha M; Wang Y; Sun J; Chen J; Wang Y; Tong C
J Cancer Res Clin Oncol; 2012 Feb; 138(2):231-8. PubMed ID: 22102173
[TBL] [Abstract][Full Text] [Related]
56. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.
Pujol JL; Breton JL; Gervais R; Rebattu P; Depierre A; Morère JF; Milleron B; Debieuvre D; Castéra D; Souquet PJ; Moro-Sibilot D; Lemarié E; Kessler R; Janicot H; Braun D; Spaeth D; Quantin X; Clary C
Ann Oncol; 2005 Apr; 16(4):602-10. PubMed ID: 15741225
[TBL] [Abstract][Full Text] [Related]
57. Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Najjar F; Al-Massarani G; Banat I; Alammar M
Int J Biol Markers; 2015 Nov; 30(4):e374-81. PubMed ID: 26109363
[TBL] [Abstract][Full Text] [Related]
58. Platinum doublets as first-line treatment for elderly patients with advanced non-small cell lung cancer.
Piacentini P; Greco F; Mercanti A; Trolese AR; Durante E; Moratello G; Tognetto M; Furini L; Giuliani J; Bonetti A
Tumori; 2013; 99(6):650-5. PubMed ID: 24503786
[TBL] [Abstract][Full Text] [Related]
59. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival.
Liu L; Wu C; Wang Y; Zhong R; Duan S; Wei S; Lin S; Zhang X; Tan W; Yu D; Nie S; Miao X; Lin D
J Thorac Oncol; 2011 Nov; 6(11):1793-800. PubMed ID: 21841506
[TBL] [Abstract][Full Text] [Related]
60. The associations of TERT-CLPTM1L variants and TERT mRNA expression with the prognosis of early stage non-small cell lung cancer.
Chen Z; Wang J; Bai Y; Wang S; Yin X; Xiang J; Li X; He M; Zhang X; Wu T; Xu P; Guo H
Cancer Gene Ther; 2017 Jan; 24(1):20-27. PubMed ID: 27982019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
